When Standard Testing Hasn't Given You an Answer

UTI Max

Unlock the Power of Precise Diagnostics for Urinary Tract Infections

Deeper Detection. Broader Resistance Coverage. Real Answers.

Some UTIs do not resolve. The patient cycles through infection after infection despite appropriate therapy. The culture comes back "no growth" while the symptoms are obviously real. The first-line antibiotic fails, and then the second one does too. These are the cases standard testing was never built for. UTI Max was. It is a proven, comprehensive PCR UTI test covering a broad range of urinary pathogens, with expanded antibiotic resistance detection spanning ESBL, carbapenemase, and MRSA markers — and the polymicrobial detection that culture is structurally incapable of providing.

Key Benefits:

Identify a comprehensive range of pathogens in a single test

Proven through a randomized clinical trial to improve patient outcomes and clinical cure rates

Expanded antibiotic resistance detection — including ESBL, carbapenemase, and MRSA markers

Detect polymicrobial infections that culture routinely misses

Get an actionable result when culture reports "no growth"

Purpose-built for recurrent (rUTI) and complicated (cUTI) presentations

Results typically in 24-48 hours or less from receipt

When Standard UTI Testing Falls Short

The Clinical Reality of Recurrent and Complicated Infection

Recurrent UTI patients are among the most frustrating in urologic and primary care. They present again and again, they are treated appropriately each time, and they come back anyway. Complicated UTI — structural abnormality, indwelling catheter, immunosuppression, poorly controlled diabetes — layers additional risk on top of an already difficult diagnostic picture.

Culture's limitations compound in exactly these patients. Biofilm-associated organisms resist cultivation. Fastidious pathogens report as no growth. Prior antibiotic exposure — which nearly every one of these patients has — suppresses growth and produces a falsely negative result. And polymicrobial communities, which are strongly associated with recurrence, are collapsed into a single reported organism or written off as contamination.

UTI Max was designed for these patients. It detects a substantially broader pathogen set, screens a comprehensive panel of resistance genes across multiple antibiotic classes, and reports every organism present rather than only the one that grew fastest.

What Comprehensive Molecular Testing Gives You:

Organisms culture cannot grow. Fastidious, slow-growing, and biofilm-associated pathogens are detected on DNA, not on a plate.

The full polymicrobial picture. See every organism in the specimen — one of the greatest advantages PCR holds over culture, and one culture cannot close.

Resistance across drug classes. ESBL, carbapenemase, fluoroquinolone, sulfa, macrolide, tetracycline, vancomycin, and methicillin markers in one run.

A result after antibiotic exposure. PCR still detects pathogen DNA in patients who have already been treated — precisely the patients culture fails.

UTI Max vs. Culture & Sensitivity

Beyond Culture: A Superior Approach to Complex UTI Diagnosis

UTI Max (PCR)

  • Quick results expedite the treatment decision
  • Enhanced accuracy minimizes false results
  • Detects the full polymicrobial community, not just the dominant organism
  • Resistance gene detection across multiple antibiotic classes
  • PCR will provide a result — even after antibiotic exposure
  • Promotes antibiotic stewardship

Culture & Sensitivity

  • Extended turnaround time postpones treatment
  • Higher potential for false negatives
  • Cultures may overlook pathogens that resist cultivation
  • Elusive and slow-growing pathogens result as "no growth"
  • Polymicrobial infection frequently misread as contamination
  • Slow resulting creates poor antibiotic stewardship

Proven in a Randomized Multicenter Trial

Sponsored by Us. Prospective. Randomized. 773 Patients. 6 U.S. Sites. PCR-Guided Management Outperformed Culture on Every Endpoint That Matters.

This isn't a theoretical claim about molecular testing, and it isn't drawn from someone else's literature. It comes from a trial we sponsored — conducted independently and prospectively by a third-party CRO. In a multicenter randomized controlled trial of 773 patients across six U.S. sites, adults with complicated UTI were managed either on PCR results or on conventional culture and sensitivity results. Physicians acted on whichever result they were randomized to receive, blinded to the other. PCR-guided management won on speed, on detection, on antibiotic choice, and — most importantly — on whether the patient actually got better.

Stat 1 — Speed: Roughly 2 days faster to an actionable result — 49.7 hours vs. 104.4 hours with culture

Stat 2 — Detection: 43.5% polymicrobial detection vs. 31.9% with culture

Stat 3 — Antibiotic choice: 83.4% appropriate antibiotic selection vs. 62.1% with culture

Stat 4 — Cure: 74.1% complete clinical cure vs. 62.7% with culture

Stat 5 — Overall outcome: 88.1% favorable clinical outcome vs. 78.1% with culture

Most diagnostics marketing argues from mechanism — "PCR is more sensitive, therefore better care." This trial closes that loop with outcomes. An 11.4-point improvement in complete clinical cure isn't a lab metric — it's a patient outcome, and it's specific to our test and our SOPs. Other diagnostics companies argue that better sensitivity should lead to better care but haven’t proven it.

Trial registry: ClinicalTrials.gov NCT06996301

Citation — Part I: Spangler FL, Williams C, Aberger ME, et al. Clinical utility of PCR compared to conventional culture and sensitivity testing for the management of complicated urinary tract infections in adults: Part I — clinical outcomes, investigator satisfaction scores, and turnaround times. Diagn Microbiol Infect Dis. 2025;111:116601. 

Citation — Part II: Spangler FL, Williams C, Aberger ME, et al. Clinical utility of PCR compared to conventional culture and sensitivity testing for the management of complicated urinary tract infections in adults: Part II — diagnostic concordance, discordant results, and antimicrobial selection efficacy. Diagn Microbiol Infect Dis. 2025;111:116646.

The Comprehensive UTI Max Test

Broad Pathogen and Resistance Coverage in a Single Specimen

UTI Max detects a comprehensive range of urinary pathogens — including atypical and difficult-to-culture organisms that standard testing routinely misses — along with expanded antibiotic resistance across multiple drug classes. Every report identifies each organism present, its relative microbial load, and the resistance markers that guide antibiotic selection.

  • Specimen Type: Clean catch urine
  • Turnaround Time:Results typically in 24-48 hours or less from receipt

Who Should Order UTI Max

For the Cases That Have Not Responded to Anything Else

Recurrent UTI patients. Multiple infections despite appropriate treatment. Standard testing has not identified the cause. UTI Max is particularly strong at surfacing the polymicrobial infections that drive recurrence.

Complicated UTI. Structural abnormalities, catheter-associated infection, immunocompromised patients, poorly controlled diabetes. Complex presentations need comprehensive testing.

Treatment failures. The antibiotics are not working, the cultures are inconclusive, and the patient is losing faith. UTI Max is built to find what other testing misses.

"No growth" with obvious symptoms. When culture and clinical picture disagree, culture is usually the one that is wrong. PCR does not need the organism to grow.

WHICH UTI TEST SHOULD I ORDER?

 

UTI Max UTI Express™
Best for Recurrent, complicated, treatment-failure UTI Routine, suspected UTI
Pathogen coverage Comprehensive, including atypical organisms Core UTI organisms
Resistance detection Expanded, incl. ESBL and carbapenemase Key resistance markers
Polymicrobial detection Yes — expanded Yes
Turnaround Typically 24-48 hrs Typically 24-48 hrs
Specimen Clean catch urine Clean catch urine

Our Advanced Diagnostics Testing

The SoftCell Standard, Every Test, Every Time

At SoftCell, every test we run is backed by advanced, precision-engineered instrumentation, rigorously validated protocols, and a team that refuses to cut corners. Our experienced, expert team holds every result to strict quality assurance standards — because "close enough" isn't in our vocabulary. As a CLIA-certified reference laboratory powered by Doc Lab — the same team behind the science and development of our core reagents — we offer something most labs can't: tighter quality control, faster problem resolution, and technical support from the people who built the test.

Ordering Information

Effortless Access to Advanced Diagnostics

Ordering is simple, and results are delivered how you prefer: secure web portal, fax, or EMR integration. New accounts are set up fast, complete with kits, requisitions, and portal access. For any questions or assistance, our dedicated client services team is here to help. Contact us at info@SoftCellLabs.com or (503) 402-2505.

Experience the SoftCell Difference

Where Innovation Meets Clinical Excellence

Trust SoftCell for your reference laboratory needs and unlock the power of precise, personalized medicine. Our advanced testing can make a significant difference in your practice through improved patient outcomes and more efficient treatment plans. Work with a lab partner that actually answers the phone.